Clinical trial documentation is one of the most expensive bottlenecks in drug development.
Protocols, informed consent forms, investigator brochures, DSURs and CSRs require structured drafting, repeated review cycles, source consistency, version control and regulatory alignment. When this process slows down, the impact is not limited to writing cost. It can affect submission timing, amendment burden, site readiness and commercial timelines.
The strongest ROI case for AI regulatory document generation comes from four areas: faster first drafts, shorter review cycles, reduced amendment risk and better use of specialist medical writing capacity.
The key is not replacing expert review. The real value comes from generating structured, source grounded drafts faster, while keeping human oversight, audit trails and compliance controls intact.